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Abstract
Background: Visual hallucinations are commonly seen in various neurological and psychiatric disorders including
schizophrenia. Current models of visual processing and studies in diseases including Parkinsons Disease and Lewy
Body Dementia propose that Acetylcholine (Ach) plays a pivotal role in our ability to accurately interpret visual
stimuli. Depletion of Ach is thought to be associated with visual hallucination generation. AchEI’s have been used
in the targeted treatment of visual hallucinations in dementia and Parkinson’s Disease patients. In Schizophrenia, it
is thought that a similar Ach depletion leads to visual hallucinations and may provide a target for drug treatment
Case Presentation: We present a case of a patient with Schizophrenia presenting with treatment resistant and
significantly distressing visual hallucinations. After optimising treatment for schizophrenia we used Rivastigmine,
an AchEI, as an adjunct to treat her symptoms successfully.
Conclusions: This case is the first to illustrate this novel use of an AchEI in the targeted treatment of visual
hallucinations in a patient with Schizophrenia. Targeted therapy of this kind can be considered in challenging cases
although more evidence is required in this field.
Background
Visual hallucinations occur in a variety of neurological
and psychiatric disorders and are prominent in the
dementias and psychotic illness. The treatment of this
distressing symptom often targets the underlying illness
rather than the symptom. The pathophysiology of visual
hallucinatory generation however remains unclear and
more recent research has focused on acetylcholine
depletion and its association with visual hallucinations.
To be able to better understand visual hallucinatory
experience, we must first consider how normal cognitive
processing enables the brain to process elementary
visual stimuli and convert them into meaningful per-
cepts. Bayesian statistical principles offer an elegant
model on which to conceptualise the visual pathway. It
is proposed that ascending stimulus driven and descend-
ing context driven pathways combine in an iterative
manner to produce an accurate visual experience of our
surroundings [1,2]. Acetylcholine is thought to play a
pivotal role in modulating this pathway with low levels
correlating to a greater degree of context driven visual
representations and thus contextual inaccuracy [3]. This
contextual inaccuracy could explain visual hallucinations
as images would be perceived despite their absence in
external space.
Diseases with significant Ach depletion include the
dementias (in particular Lewy Body Dementia) and Par-
kinson’s Disease. Drug therapies to increase levels of
Ach are readily available (AchEI’s) and there is evidence
to suggest their efficacy in the treatment of visual hallu-
cinations in these conditions [4-8] Utilising current
models of visual hallucination generation and evidence
for the use of AchEI’s in related disorders it would
appear that Ach depletion also plays a similar role in
Schizophrenia.
We present below a case of a patient with treatment
resistant schizophrenia presenting with distressing visual
hallucinations who we successfully treated with an
AchEI, Rivastigmine.
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Case Presentation
Mrs A is a 43 year old female with a diagnosis of schi-
zoaffective disorder. She was transferred to the National
Psychosis Unit, a tertiary referral in-patient service
which specialises in the management of treatment resis-
tant psychotic illness. On admission she presented as
dishevelled, agitated, thought disordered and labile in
mood. She expressed grandiose and paranoid delusions,
3rd person auditory hallucinations and visual hallucina-
tions of large wild cats. Negative features included
apathy and withdrawal. Mrs A had little insight into her
illness. These symptoms had persisted largely unchanged
despite in-patient management and compliance with
antipsychotic and mood stabilising medications for the
previous 6 months. These visual experiences were evi-
dent during the day in clear daylight and consciousness,
but worse at night when she was alone in her bedroom;
on admission, she would choose to sleep in the corridor
so as to avoid these creatures- and had been doing so
for over 6 months.
Mrs A first became unwell with features of a schizoaf-
fective disorder at the age of 19. Following treatment
and discharge there was a period of relative stability
over the next 20 years during which she was under the
care of her local community mental health team
(CMHT). At the age of 40, Mrs A was again admitted
following a breakdown in her ability to function in the
community due to deterioration in her mental state.
Various treatment strategies were utilised during this
period, including clozapine, following failure of combi-
nations of other atypical antipsychotics and mood stabi-
lisers. She had responded well to a combination of
clozapine, aripiprazole and escitalopram in terms of a
reduction in persecutory delusions and auditory halluci-
nations, however her visual hallucinations remained
vivid. These had then taken greater prominence in Mrs
A’s mental state and this subsequently led to more sub-
jective distress. Socially she was quite isolative and did
not maintain any relations with family or friends Her
presentation was not thought to be related to non com-
pliance, drug and alcohol misuse or psychosocial stres-
sors. Physical Investigations were unremarkable. MRI
and EEG were reported as normal and blood indices
including thyroid function tests, copper, caeruloplasmin
and autoantibody screens were negative.
Mrs A’s PANSS score on admission was 79 (p30, n15,
g34) and MMSE was 30/30. The pharmacological man-
agement plan was to commence and maintain semi-
sodium valproate within therapeutic plasma levels,
reduce and discontinue her clonazepam and to restabi-
lise on clozapine therapy. Following 4 months of this
therapy with clozapine at a dose of 450 mg per day and
in combination with psychological and occupational
therapy, Mrs A’s mental state stabilised with marked
improvement in her delusions and auditory hallucina-
tions, stable mood and better function. Her PANSS rat-
ing improved to a total score of 52 (p14, n13, g 25).
Despite these improvements on clozapine, Mrs A con-
tinued to experience vivid visual hallucinations of tigers
and lions.
A decision was made by the multidisciplinary team to
begin an AChEI, Rivastigmine to target visual hallucina-
tion symptoms. Rivastigmine patches at 4.6 mg/24 hrs
was initiated. No changes were made to all other psy-
chotropic medications. PANSS rating scales and MMSE
scores were done on two occasions following the addi-
tion of rivastigmine patches to therapy. In addition a tai-
lored visual hallucination rating scale was developed,
adapted from the Psychotic Symptom Rating Scales for
auditory hallucinations (PSYRATS) [9]. This consisted
of 3 items measuring frequency, vividness and distress
associated with the hallucinations. Items were scored
0-4 (frequency and distress) or 0-3 (vividness), and were
clinician-rated. Ratings were taken daily by the primary
or allocated nurse in the two weeks prior to treatment
with rivastigmine and during treatment.
Mrs A continued to show an improvement in her
functioning, demonstrated by the fact she now slept
consistently in her own bedroom at night, was indepen-
dent in her self-care, and started to participate in com-
munity outings and OT activities. Mrs A’s level of
occupational and psychological therapy input remained
stable throughout the introduction of rivastigmine
patches, and focused on reducing the distress and inter-
ference with daily activities associated with the visual
hallucinations. No further medication changes were
made to her pharmacological therapy. Mrs A suffered
no untoward side effects from the rivastigmine patches.
Two weeks following the addition of rivastigmine
patches her PANSS total score was 45 (P 13, N 10, GP
22) and this improvement was maintained as her
PANSS total score at 7 weeks was 43 (P 11, N 10, GP
22). Over the baseline assessment period, Mrs A contin-
ued to report distressing visual hallucinations through-
out the day. After the rivastigmine treatment was
initiated, after 3 weeks of treatment, reporting of visual
hallucinations was decreased to once a day on average,
and the level of distress was significantly reduced. This
one appearance a day was usually reported as seeing a
lion or tiger in her bedroom when she woke up in the
middle of the night. Slowly, even this report became
much more ambiguous; the animals were more unclear
at night and she had more difficulty making them out.
Subjectively, Mrs. A reported that she thought the
patches were helpful and she was seeing the animals
less frequently than before. She was discharged from
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hospital and at 6 month follow up was living indepen-
dently quite successfully, with support from her locality
mental health team, and remaining free from visual hal-
lucinations and continuing her rivastigmine.
Conclusions
This case illustrates a novel use for AchEI’s in the tar-
geted treatment of visual hallucinations in Schizophre-
nia. Often the most challenging cases faced in clinical
psychiatry are those with treatment resistant symptoms
which can prove distressing to patients. Our approach
in this case was to combine current thinking in neuro-
physiology and therapeutic evidence in related disorders
and then to apply these to clinical practice in a targeted
way. We appreciate that this is a single case and a novel
therapeutic use however we feel that further research in
this field is indicated.
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